Advanced Therapy Medicinal Products CDMO Market by Products, Phase, Indication, End-Users

Description

List of Tables

[186 Pages Report] The Advanced Therapy Medicinal Products CDMO Market size was estimated at USD 7.54 billion in 2023 and expected to reach USD 8.74 billion in 2024, at a CAGR 17.06% to reach USD 22.74 billion by 2030.

Global Advanced Therapy Medicinal Products CDMO Market

KEY MARKET STATISTICS
Base Year [2023]	USD 7.54 billion
Estimated Year [2024]	USD 8.74 billion
Forecast Year [2030]	USD 22.74 billion
CAGR (%)	17.06%

Advanced Therapy Medicinal Products CDMO Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Advanced Therapy Medicinal Products CDMO Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Advanced Therapy Medicinal Products CDMO Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Advanced Therapy Medicinal Products CDMO Market, highlighting leading vendors and their innovative profiles. These include Abzena, Advanced Therapies, Inc. by WuXi AppTec, AGC Inc., Aldevron, Almac Group, Arranta Bio Holdings, LLC, Bio Elpida, BlueReg, Catalent Inc., CELONIC Group, CGT Catapult, Charles River Laboratories International, Inc., Coriolis Pharma Research GmbH, Eurofins Scientific SE, FUJIFILM Corporation, Lonza Group, Minaris Regenerative Medicine, Oxford Biomedica PLC, Patheon by Thermo Fisher Scientific Inc., Rentschler Biopharma SE, REPROCELL Inc., RoslinCT, Samsung Biologics, and VIVEBIOTECH S.L..

Market Segmentation & Coverage

This research report categorizes the Advanced Therapy Medicinal Products CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:

Products
- Cell Therapy
- Gene Therapy
- Tissue Engineered
Phase
- Phase I
- Phase II
- Phase III
- Phase IV
Indication
- Cardiology
- Central Nervous System
- Dermatology
- Endocrine, Metabolic, Genetic
- Gastroenterology
- Hematology
- Immunology & Inflammation
- Infectious Disease
- Musculoskeletal
- Oncology
- Ophthalmology
End-Users
- Academic and Research Institutions
- Biotechnology & Pharmaceutical Companies
- Clinical Research Organizations (CROs)
- Hospitals and Clinics
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Advanced Therapy Medicinal Products CDMO Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Advanced Therapy Medicinal Products CDMO Market?

3. What are the technology trends and regulatory frameworks in the Advanced Therapy Medicinal Products CDMO Market?

4. What is the market share of the leading vendors in the Advanced Therapy Medicinal Products CDMO Market?

5. Which modes and strategic moves are suitable for entering the Advanced Therapy Medicinal Products CDMO Market?

Product Code: MRR-3A2E844FDD16

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Advanced Therapy Medicinal Products CDMO Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Proliferation in prevalence of rare diseases with growing emergence of novel

infectious diseases

5.1.1.2. Rising numbers of clinical trials for development of advanced therapy medicinal products
5.1.1.3. Increasing investments in pharmaceutical research and development worldwide

5.1.2. Restraints
- 5.1.2.1. High cost associated with outsourcing ATMP solutions
5.1.3. Opportunities
- 5.1.3.1. Adoption of advanced technologies by advanced therapy medicinal

products CDMOs

5.1.3.2. Strategic alliance and expansion activities for R&D of advanced therapy medicinal products

5.1.4. Challenges
- 5.1.4.1. Stringent governmental rules and regulations for ATMP approvals and

commercialization

5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Advanced Therapy Medicinal Products CDMO Market, by Products

6.1. Introduction
6.2. Cell Therapy
6.3. Gene Therapy
6.4. Tissue Engineered

7. Advanced Therapy Medicinal Products CDMO Market, by Phase

7.1. Introduction
7.2. Phase I
7.3. Phase II
7.4. Phase III
7.5. Phase IV

8. Advanced Therapy Medicinal Products CDMO Market, by Indication

8.1. Introduction
8.2. Cardiology
8.3. Central Nervous System
8.4. Dermatology
8.5. Endocrine, Metabolic, Genetic
8.6. Gastroenterology
8.7. Hematology
8.8. Immunology & Inflammation
8.9. Infectious Disease
8.10. Musculoskeletal
8.11. Oncology
8.12. Ophthalmology

9. Advanced Therapy Medicinal Products CDMO Market, by End-Users

9.1. Introduction
9.2. Academic and Research Institutions
9.3. Biotechnology & Pharmaceutical Companies
9.4. Clinical Research Organizations (CROs)
9.5. Hospitals and Clinics

10. Americas Advanced Therapy Medicinal Products CDMO Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Advanced Therapy Medicinal Products CDMO Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Advanced Therapy Medicinal Products CDMO Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

14.1. Key Company Profiles
- 14.1.1. Abzena
- 14.1.2. Advanced Therapies, Inc. by WuXi AppTec
- 14.1.3. AGC Inc.
- 14.1.4. Aldevron
- 14.1.5. Almac Group
- 14.1.6. Arranta Bio Holdings, LLC
- 14.1.7. Bio Elpida
- 14.1.8. BlueReg
- 14.1.9. Catalent Inc.
- 14.1.10. CELONIC Group
- 14.1.11. CGT Catapult
- 14.1.12. Charles River Laboratories International, Inc.
- 14.1.13. Coriolis Pharma Research GmbH
- 14.1.14. Eurofins Scientific SE
- 14.1.15. FUJIFILM Corporation
- 14.1.16. Lonza Group
- 14.1.17. Minaris Regenerative Medicine
- 14.1.18. Oxford Biomedica PLC
- 14.1.19. Patheon by Thermo Fisher Scientific Inc.
- 14.1.20. Rentschler Biopharma SE
- 14.1.21. REPROCELL Inc.
- 14.1.22. RoslinCT
- 14.1.23. Samsung Biologics
- 14.1.24. VIVEBIOTECH S.L.
14.2. Key Product Portfolio

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing